ARCHIVES

NCI-Approved Clinical Trials

This article is from The Cancer Letter archive.

Vol. 27 No. 12 | December 31, 2004

Download PDF Visit The Full Archive

Related Articles

Afinitor and Exemestane More Than Doubles PFS, Reduces Progression Risk by 57 Percent

September 30, 2011

NCI To Place 20% Cap On Grant Renewal Increases.

May 25, 2001

Big Get Bigger, Litton Primate Contract Renewed

September 19, 1975

NCI Letter To Pittsburgh Details Deficiencies In NSABP Operations

April 8, 1994

Erbitux Plus Chemo Effective For NSCLC; Carboplatin Prevents Testicular Recurrence

July 25, 2008

NCI-Approved Clinical Trials

July 30, 2010